Sumitomo Mitsui Trust Holdings Inc. Sells 41,088 Shares of Hologic, Inc. (NASDAQ:HOLX)

Sumitomo Mitsui Trust Holdings Inc. decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.4% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 601,270 shares of the medical equipment provider’s stock after selling 41,088 shares during the quarter. Sumitomo Mitsui Trust Holdings Inc.’s holdings in Hologic were worth $42,961,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in HOLX. McGlone Suttner Wealth Management Inc. bought a new position in shares of Hologic during the 4th quarter worth $27,000. Venturi Wealth Management LLC purchased a new position in Hologic in the third quarter valued at about $29,000. NBC Securities Inc. bought a new position in Hologic in the third quarter worth about $33,000. Bartlett & CO. Wealth Management LLC purchased a new stake in shares of Hologic during the fourth quarter valued at about $33,000. Finally, Deseret Mutual Benefit Administrators boosted its holdings in shares of Hologic by 42.2% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 522 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 155 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Insider Buying and Selling

In related news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Hologic news, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total value of $111,647.65. Following the completion of the transaction, the director now directly owns 1,572 shares of the company’s stock, valued at $119,802.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the transaction, the director now directly owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The disclosure for this sale can be found here. Insiders sold 32,846 shares of company stock valued at $2,473,443 over the last quarter. 1.75% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

HOLX has been the subject of several recent analyst reports. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Evercore ISI increased their price objective on Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. UBS Group raised their price objective on Hologic from $78.00 to $79.00 and gave the stock a “neutral” rating in a research report on Friday, February 2nd. William Blair reissued an “outperform” rating on shares of Hologic in a research report on Friday, February 2nd. Finally, Raymond James raised their price objective on Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $87.00.

Hologic Trading Up 0.4 %

Shares of NASDAQ:HOLX opened at $75.38 on Friday. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88. The stock has a market cap of $17.69 billion, a price-to-earnings ratio of 35.73, a PEG ratio of 2.54 and a beta of 1.00. The business has a 50-day moving average price of $75.75 and a 200-day moving average price of $72.54.

Hologic (NASDAQ:HOLX) last released its earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The firm had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. During the same quarter in the previous year, the company posted $1.07 earnings per share. The company’s revenue was down 5.7% compared to the same quarter last year. Equities analysts predict that Hologic, Inc. will post 4.01 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.